Gabapentin (All indications) updated on 04-22-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16070
R66689		 Christensen (Gabapentin) (All indications) (Controls exposed to LTG), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.28 [0.99;1.64] C
excluded (control group) 		76/1,336   395/8,756 471 1,336
ref
S16034
R66555		 Christensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.25 [0.98;1.59] 76/1,336   141,442/4,467,848 141,518 1,336
ref
S10095
R36745		 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 2.17 [1.54;3.05] C
excluded (control group) 		47/378   179/2,916 226 378
ref
S8517
R28088		 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 2.51 [1.85;3.41] C 47/378   91,455/1,710,441 91,502 378
ref
Total 2 studies 1.76 [0.89;3.49] 233,020 1,714
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024Christensen, 2024 1 1.25[0.98; 1.59]141,5181,33651%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 2 2.51[1.85; 3.41]91,50237849%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 92% 1.76[0.89; 3.49]233,0201,7140.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Gabapentin) (All indications) (Controls unexposed, general population; 2: Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.76[0.89; 3.49]233,0201,71492%NAChristensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.76[0.89; 3.49]233,0201,71492%NAChristensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2 Tags Adjustment   - No  - No 2.51[1.85; 3.41]91,502378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1   - Yes  - Yes 1.25[0.98; 1.59]141,5181,336 -NAChristensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024 1 All studiesAll studies 1.76[0.89; 3.49]233,0201,71492%NAChristensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10095, 16070

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.76[0.89; 3.49]233,0201,71492%NAChristensen (Gabapentin) (All indications) (Controls unexposed, general population), 2024 Coste (Controls unexposed, NOS) (Mixed indications), 2020 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.64[0.98; 2.76]6971,71483%NAChristensen (Gabapentin) (All indications) (Controls exposed to LTG), 2024 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 20.510.01.0